@article{TAU19832,
author = {Alan Dal Pra and Matthew C. Abramowitz and Radka Stoyanova and Alan Pollack},
title = {Contemporary role of postoperative radiotherapy for prostate cancer},
journal = {Translational Andrology and Urology},
volume = {7},
number = {3},
year = {2018},
keywords = {},
abstract = {While radical prostatectomy (RP) has provided long-term disease control for the majority of patients with localized prostate cancer (CaP), nearly 30% of all surgical patients have disease progression. For high-risk patients, more than half of men experience disease recurrence within 10 years. Postoperative radiotherapy is the only known potentially curative treatment for a large number of patients following prostatectomy. Lately, there have been several advances with the potential to improve outcomes for patients undergoing postoperative radiotherapy. This article will give an overview of the existing literature and current controversies on: (I) timing of postoperative radiation; (II) use of concomitant androgen deprivation therapy; (III) optimal dose to the prostate bed; (IV) use of hypofractionation; (V) elective treatment of the pelvic lymph nodes; (VI) novel imaging modalities, and (VII) genomic biomarkers.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/19832}
}